Proxalutamide
- Generic Name
- Proxalutamide
- Drug Type
- Small Molecule
- Chemical Formula
- C24H19F4N5O2S
- CAS Number
- 1398046-21-3
- Unique Ingredient Identifier
- QX6O64GP40
- Background
Proxalutamide is under investigation in clinical trial NCT03899467 (The Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer).
- Indication
用于转移性去势抵抗性前列腺癌（mCRPC）和转移性乳腺癌患者的治疗。
The South Proxa-Rescue AndroCoV Trial Against COVID-19
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Corpometria Institute
- Target Recruit Count
- 133
- Registration Number
- NCT05126628
- Locations
- 🇧🇷
Corpometria Institute, Brasília, DF, Brazil
Neoadjuvant Therapy With Proxalutamide Combined With Androgen Deprivation Therapy（ADT）for High Risk Prostate Cancer
- Conditions
- Neoadjuvant Therapy \High Risk Prostate Cancer
- Interventions
- Other: placebo
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Hongqian Guo
- Target Recruit Count
- 2
- Registration Number
- NCT05076851
- Locations
- 🇨🇳
The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects
- Conditions
- Covid19
- Interventions
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Suzhou Kintor Pharmaceutical Inc,
- Target Recruit Count
- 139
- Registration Number
- NCT05009732
- Locations
- 🇨🇳
Shanghai Public Health Clinical Center, Jinshan, Shanghai, China
🇵🇭Philippine General Hospital, Malina, Metro Malina, Philippines
🇵🇭St. Paul's Hospital, Iloilo City, Iloilo, Philippines
Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- Suzhou Kintor Pharmaceutical Inc,
- Target Recruit Count
- 733
- Registration Number
- NCT04870606
- Locations
- 🇺🇸
Olivo Medical and Wellness Center, Chicago, Illinois, United States
🇺🇸Absolute Clinical Research, Phoenix, Arizona, United States
🇺🇸Long Beach Clinical Trials, Long Beach, California, United States
Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit
- Conditions
- Covid19SARS (Severe Acute Respiratory Syndrome)
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- Applied Biology, Inc.
- Registration Number
- NCT04853927
- Locations
- 🇧🇷
Samel Hospital, Manaus, Amazonas, Brazil
Proxalutamide Treatment for COVID-19 Female Outpatients
- Conditions
- Covid19SARS-CoV Infection
- Interventions
- Other: Standard of Care
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- Applied Biology, Inc.
- Registration Number
- NCT04853134
- Locations
- 🇧🇷
Corpometria Institute, Brasilia, Brazil
Proxalutamide Treatment for Hospitalized COVID-19 Patients
- Conditions
- Covid19SARS (Severe Acute Respiratory Syndrome)
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2021-06-24
- Lead Sponsor
- Applied Biology, Inc.
- Target Recruit Count
- 645
- Registration Number
- NCT04728802
- Locations
- 🇧🇷
Hospital Oscar Nicolau, Manaus, Amazonas, Brazil
🇧🇷Hospital Raimunda Francisca Dinelli da Silva, Maues, Amazonas, Brazil
🇧🇷Hospital Regional José Mendes, Itacoatiara, Amazonas, Brazil
Anti-Androgen Treatment for COVID-19
- Conditions
- SARS (Severe Acute Respiratory Syndrome)SARS-CoV2Androgenetic AlopeciaBenign Prostatic HyperplasiaCOVID-19Prostate Cancer
- Interventions
- Other: Standard of Care
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Applied Biology, Inc.
- Target Recruit Count
- 268
- Registration Number
- NCT04446429
- Locations
- 🇧🇷
Corpometria Institute, Brasilia, Brazil
Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Suzhou Kintor Pharmaceutical Inc,
- Target Recruit Count
- 63
- Registration Number
- NCT04103853
- Locations
- 🇨🇳
Sun-Yat-sen University Cancer center, Guangzhou, Fujian, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC
- Conditions
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Interventions
- First Posted Date
- 2019-04-02
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Suzhou Kintor Pharmaceutical Inc,
- Target Recruit Count
- 61
- Registration Number
- NCT03899467
- Locations
- 🇺🇸
G U Research Network, Omaha, Nebraska, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
🇺🇸Greenville Health System, Greenville, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.